Navigation Links
YM BioSciences reports second quarter 2010 operational and financial results
Date:2/8/2010

MISSISSAUGA, ON, Feb. 8 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX: YM), today reported operational and financial results for the second quarter of fiscal 2010, ended December 31, 2009.

"After rigorous evaluation of numerous global in-licensing opportunities, we proposed to merge Cytopia Limited., a clinical-stage, Melbourne-based drug development company, into YM during the second quarter," said David Allan, Chairman & CEO of YM BioSciences Inc. "Cytopia products are an ideal complement to our current portfolio and this merger provides all shareholders both risk mitigation and a much enhanced prospect for success through the opportunity to link Cytopia's earlier stage products in development to our well-advanced development of nimotuzumab both directly and through our extensive network of international licensees. Subsequent to quarter-end, the merger was completed. The combination of YM and Cytopia is completely aligned with the YM business model to continuously renew our pipeline through additions of promising new drug candidates from the basic research of other organizations."

Highlights for the second quarter of Fiscal 2010:

    -   Signed agreement with Therapure Biopharma, under which it will
        formulate and fill nimotuzumab into sterile vials in its aseptic,
        GMP-certified, and Health Canada-licensed fill suite in Mississauga,
        Canada.

    -   Utilizing YM's IntelliMab(TM) technology, the collaboration between
        the National Research Council of Canada's Biotechnology Research
        Institute (NRC-BRI) and YM resulted in a number of antibodies that
        bind optimally to HER2/neu-over-expressing breast cancer cells while
        minimally binding to HER2 on normal cardiac cells.

    -   Cytopia 
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
5. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
6. YM BioSciences announces result of Cytopia shareholder vote
7. Profectus Biosciences to Present at Key Investor Conference in January 2010
8. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
9. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
10. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
11. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PHILADELPHIA , Nov. 26, 2014 /PRNewswire-USNewswire/ ... unforgiving environments. Human exploration of space requires astronauts to ... mission safety and success, and prevent potential errors and ... success, little is known about how cognition is affected ... primarily affected. Now, Penn Medicine researchers are ...
(Date:11/26/2014)... On January, 14, 2015, UMBC’s Biotechnology ... science community to the UMBC campus for a discussion ... Protein Society, will take place from 9 a.m. to ... Through discussion, presentations and workshops, the free symposium will ... role in the industry and the future of protein ...
(Date:11/26/2014)... PMG Research, Inc. announced today the formation ... of sites that provide clinical research services to pharmaceutical companies ... through its partnerships with large physician practices and integrated health ... in the Southeastern United States and spans over 60 physician ... will be held by: Dr. Robert Holmes, MD, of ...
(Date:11/26/2014)... NC (PRWEB) November 25, 2014 ... Intensity Focused Ultrasound (HIFU) devices, recently participated in ... Small Renal Mass 360° .” Key opinion leaders ... therapeutic advances related to small renal masses while ... about different ablative technologies in hands-on labs. Attendees ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3
... Nov. 15 China Aoxing Pharmaceutical,Company, Inc. (OTC ... and product pipeline for highly regulated narcotic,medicines and ... the first quarter of fiscal 2008 ended September ... revenues of $1,380,294 for,the first quarter of fiscal ...
... Final Close Completes $35 Million Financing, WOBURN, Mass., ... new generation biologics for the treatment and,prevention of cancer ... E financing, concurrent with the completion of a,venture debt ... BioVex intends to use the capital to complete its ...
... NASA Goddard Space Flight Center in Greenbelt, Md. ... nanotubes (CNT) has been named a winner in the ... Technology category. This award will be celebrated at the ... Tech Briefs National Nano Engineering Conference (NNEC 2007) in ...
Cached Biology Technology:China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 2China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 3China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 4China Aoxing Pharmaceutical Reports Financial Results for the First Quarter of Fiscal 2008 5BioVex Closes Second Round of Series E Financing 2NASA Goddard Space Flight Center's carbon nanotube manufacturing technology wins Nano 50 Award 2
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
(Date:11/4/2014)... of Utah engineers developed the first room-temperature fuel cell ... without needing to ignite the fuel. These new fuel ... power and sensors. , A study of the new ... journal ACS Catalysis . , Fuel cells convert ... fuel and an oxygen-rich source such as air. If ...
(Date:11/4/2014)... — Think about the way our bodies are assembled ... know that they are supposed to become a nerve ... find the correct place and alignment? Researchers at the ... , In a new study, UM researchers describe the ... surrounding neighbors, at the head-trunk region. Their discovery may ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2The inside story: How the brain and skull stay together 2
... And if one wants to make something work using ... behavior of cells is a good place to start ... a very tiny packet. As Erik Winfree, professor of ... "I tend to think of cells as really small ...
... Rett Syndrome Foundation (IRSF) announces today ten (10) new ... Translational Research Program; and additional funding for current human ... 2013 covers the spectrum of Rett syndrome research, from ... way to treating the girls diagnosed with Rett syndrome. ...
... more than a trillion cells called neurons that form a ... contains millions of proteins that perform different functions. Exactly how ... brain still remains as a mystery that is just beginning ... of scientists has been able to observe intact interactions between ...
Cached Biology News:Building artificial cells will be a noisy business 2Building artificial cells will be a noisy business 3IRSF announces 2013 awards and implements new Translational Program 2IRSF announces 2013 awards and implements new Translational Program 3Watching how the brain works 2
Immunogen: Extract of pigmented melanoma metastases from lymph nodes. Storage: -20 C, Avoid Freeze/Thaw Cycles...
with GlutaMAXIL-glutamine...
alpha N-catenin (C-19)...
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Biology Products: